<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Eftansomatropin alfa: what changed | Grey Peptides</title>
    <link>https://greypeptides.com/changes/#e-eftansomatropin-alfa</link>
    <atom:link href="https://greypeptides.com/changes/eftansomatropin-alfa.xml" rel="self" type="application/rss+xml" />
    <description>News, regulatory alerts, corrections and new guides about Eftansomatropin alfa on Grey Peptides, newest first.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 30 Oct 2026 12:00:00 +0000</lastBuildDate>
    <ttl>1440</ttl>
    <item>
      <title>Correction: Corrected: Eftansomatropin alfa</title>
      <link>https://greypeptides.com/corrections/#c-q1017-eftansomatropin-approval</link>
      <guid isPermaLink="false">greypeptides-changes-eftansomatropin-alfa-corr-c-q1017-eftansomatropin-approval</guid>
      <pubDate>Fri, 30 Oct 2026 12:00:00 +0000</pubDate>
      <category>Correction</category>
      <description>Not approved anywhere; a phase 3 in Chinese children met non-inferiority and a licence application is under review in China. The adult phase 2 is cited to its paper.</description>
    </item>
  </channel>
</rss>
